JP2005523318A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523318A5
JP2005523318A5 JP2003585745A JP2003585745A JP2005523318A5 JP 2005523318 A5 JP2005523318 A5 JP 2005523318A5 JP 2003585745 A JP2003585745 A JP 2003585745A JP 2003585745 A JP2003585745 A JP 2003585745A JP 2005523318 A5 JP2005523318 A5 JP 2005523318A5
Authority
JP
Japan
Prior art keywords
virus
viruses
treatment
antigen
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003585745A
Other languages
English (en)
Japanese (ja)
Other versions
JP4801880B2 (ja
JP2005523318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003994 external-priority patent/WO2003088994A2/en
Publication of JP2005523318A publication Critical patent/JP2005523318A/ja
Publication of JP2005523318A5 publication Critical patent/JP2005523318A5/ja
Application granted granted Critical
Publication of JP4801880B2 publication Critical patent/JP4801880B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003585745A 2002-04-19 2003-04-16 新生仔予防接種用変異ワクシニアウイルスアンカラ Expired - Lifetime JP4801880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200590 2002-04-19
DKPA200200590 2002-04-19
PCT/EP2003/003994 WO2003088994A2 (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010028940A Division JP2010120955A (ja) 2002-04-19 2010-02-12 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2011115564A Division JP5690214B2 (ja) 2002-04-19 2011-05-24 新生仔予防接種用変異ワクシニアウイルスアンカラ

Publications (3)

Publication Number Publication Date
JP2005523318A JP2005523318A (ja) 2005-08-04
JP2005523318A5 true JP2005523318A5 (cg-RX-API-DMAC7.html) 2006-06-08
JP4801880B2 JP4801880B2 (ja) 2011-10-26

Family

ID=29225556

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003585745A Expired - Lifetime JP4801880B2 (ja) 2002-04-19 2003-04-16 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2010028940A Pending JP2010120955A (ja) 2002-04-19 2010-02-12 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2011115564A Expired - Lifetime JP5690214B2 (ja) 2002-04-19 2011-05-24 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2014257263A Pending JP2015061876A (ja) 2002-04-19 2014-12-19 新生仔予防接種用変異ワクシニアウイルスアンカラ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010028940A Pending JP2010120955A (ja) 2002-04-19 2010-02-12 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2011115564A Expired - Lifetime JP5690214B2 (ja) 2002-04-19 2011-05-24 新生仔予防接種用変異ワクシニアウイルスアンカラ
JP2014257263A Pending JP2015061876A (ja) 2002-04-19 2014-12-19 新生仔予防接種用変異ワクシニアウイルスアンカラ

Country Status (23)

Country Link
US (3) US7897156B2 (cg-RX-API-DMAC7.html)
EP (4) EP2204179A3 (cg-RX-API-DMAC7.html)
JP (4) JP4801880B2 (cg-RX-API-DMAC7.html)
KR (2) KR20110017904A (cg-RX-API-DMAC7.html)
CN (1) CN100540051C (cg-RX-API-DMAC7.html)
AT (1) ATE366586T2 (cg-RX-API-DMAC7.html)
AU (1) AU2003239805B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309339A (cg-RX-API-DMAC7.html)
CA (1) CA2478009C (cg-RX-API-DMAC7.html)
CY (1) CY1106848T1 (cg-RX-API-DMAC7.html)
DE (1) DE60314823T3 (cg-RX-API-DMAC7.html)
DK (1) DK1420822T4 (cg-RX-API-DMAC7.html)
EA (1) EA011233B1 (cg-RX-API-DMAC7.html)
ES (1) ES2288609T5 (cg-RX-API-DMAC7.html)
IL (1) IL163701A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04010353A (cg-RX-API-DMAC7.html)
NO (1) NO336348B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ547776A (cg-RX-API-DMAC7.html)
PL (1) PL220781B1 (cg-RX-API-DMAC7.html)
PT (1) PT1420822E (cg-RX-API-DMAC7.html)
SG (1) SG173216A1 (cg-RX-API-DMAC7.html)
UA (1) UA85371C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003088994A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1335987E (pt) * 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU2003239805B2 (en) * 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
WO2004043490A1 (en) * 2002-11-07 2004-05-27 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Smallpox vaccine regimen
PT1855720T (pt) 2005-02-23 2016-12-14 Bavarian Nordic As Uso de um poxvírus modificado para a rápida indução de imunidade contra um poxvírus ou outros agentes infeciosos
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US8883168B2 (en) 2010-11-05 2014-11-11 Bavarian Nordic A/S Modulation of immune responses by the poxviral K4 protein
CN108126204A (zh) * 2011-03-11 2018-06-08 特斯通有限责任合伙公司 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
EP3639851A1 (en) * 2012-09-04 2020-04-22 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
JP6480875B2 (ja) 2013-03-15 2019-03-13 バヴァリアン・ノルディック・アクティーゼルスカブ 単一高用量のｍｖａは、新生児及び幼児において防御免疫応答を引き起こす
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
UA113442C2 (xx) 2015-01-27 2017-01-25 Ентеросорбент
CA2977660A1 (en) * 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
JP6936153B2 (ja) 2015-04-17 2021-09-15 メモリアル スローン ケタリング キャンサー センター Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
AU2017222686B2 (en) 2016-02-25 2021-12-23 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
JP7480126B2 (ja) 2018-09-15 2024-05-09 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (de) 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) † 1983-08-09 1985-02-23 Nippon Denso Co Ltd アンチスキツド制御装置
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) † 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
ATE429505T1 (de) 1996-02-21 2009-05-15 Genetic Immunity Kft Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
US6869793B2 (en) † 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998017283A1 (en) * 1996-10-25 1998-04-30 The Wistar Institute Of Anatomy & Biology Method of vaccinating infants against infections
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
WO1999007869A1 (en) 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
DE69924826T8 (de) 1998-11-18 2008-09-25 Oxford Biomedica (Uk) Ltd. Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
CN1291012C (zh) * 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 修饰的安卡拉牛痘病毒(mva)的变株
CA2409874A1 (en) 2000-05-24 2001-11-29 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
AU2001268452B2 (en) * 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
FI20030037A7 (fi) 2000-07-11 2003-03-10 Bayer Ag Parapoxvirus ovis-kantojen käyttö virusvastaisten lääkkeiden ja syövän vastaisten lääkkeiden tuottamiseksi
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
PT1335987E (pt) * 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
JP4500049B2 (ja) * 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
AU2003239805B2 (en) * 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
MXPA04011194A (es) * 2002-05-16 2005-02-14 Bavarian Nordic As Virus de viruela recombinantes que expresan los genes homologos introducidos dentro del genoma viral de la viruela.
EP1664661A4 (en) * 2003-09-10 2008-02-13 Ra Brands Llc METHOD OF PRINTING COMPOSITE VENTILATED BAND
CA2545164C (en) * 2003-11-12 2016-11-29 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Recombinant vectors expressing mucin and carcinoembryoinic antigen
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

Similar Documents

Publication Publication Date Title
JP2005523318A5 (cg-RX-API-DMAC7.html)
JP2018536433A5 (cg-RX-API-DMAC7.html)
US9707285B2 (en) Vaccination methods
JP2006501825A5 (cg-RX-API-DMAC7.html)
JP2014503206A5 (cg-RX-API-DMAC7.html)
JP2020516264A5 (cg-RX-API-DMAC7.html)
FI3371316T3 (fi) Rokotteita hepatiitti b -virusta vastaan
JP2016513115A5 (cg-RX-API-DMAC7.html)
JP2019519252A5 (cg-RX-API-DMAC7.html)
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
CA2343653A1 (en) Recombinant newcastle disease virus rna expression systems and vaccines
JP2014502156A5 (cg-RX-API-DMAC7.html)
RU2019107976A (ru) Композиция вакцины
JP2012525410A5 (cg-RX-API-DMAC7.html)
JP2017510262A5 (cg-RX-API-DMAC7.html)
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
JPWO2012053646A1 (ja) ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
WO2003046506A3 (en) Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies
Saeedi et al. Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice
Helmold et al. Advancing ORFV‐Based Therapeutics to the Clinical Stage
CN1665921A (zh) 用于免疫治疗的腺病毒载体
Moshkani et al. A highly attenuated vesicular stomatitis virus-based vaccine platform controls hepatitis B virus replication in mouse models of hepatitis B
CN106928372A (zh) 乙肝重组抗原及其表达基因、构建方法、病毒样颗粒及其制备方法、应用与疫苗